Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM001205
035-os BibID:PMID:17916982
Első szerző:Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:2007
Megjegyzések:Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SLE
antiphospholipid antibodies
thrombotic manifestation
APS
Follow-up
LAC
Primary prophylaxis
acetylsalicylic acid
antithrombocytic agent
beta2 glycoprotein 1 antibody
cardiolipin antibody
coumarin
lupus anticoagulant
phospholipid antibody
adult
antiphospholipid syndrome
article
cerebrovascular accident
cohort analysis
controlled study
data base
deep vein thrombosis
disease association
disease course
drug efficacy
female
follow uphigh risk population
history of medicine
human
international normalized ratio
lung embolism
major clinical study
male
medical record
prevalence
prophylaxis
prospective study
stroke
systemic lupus erythematosus
thrombosis
transient ischemic attack
Adult
Antibodies, Antiphospholipid
Antibody Specificity
Anticoagulants
Antiphospholipid Syndrome
Aspirin
Cohort Studies
Female
Follow-Up Studies
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Thrombosis
Time Factors
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:
Rekordok letöltése1